Rituximab for steroid-refractory chronic graft-versus-host disease.

B cells may be implicated in the pathophysiology of chronic graft-versus-host disease (GVHD), as evidenced by antibody production against sex-mismatched, Y chromosome-encoded minor HLA antigens in association with chronic GVHD. We therefore designed a phase 1/2 study of anti-B-cell therapy with rituximab in steroid-refractory chronic GVHD. Twenty-one patients were treated with 38 cycles of rituximab. Rituximab was tolerated well, and toxicity was limited to infectious events. The clinical response rate was 70%, including 2 patients with complete responses. Responses were limited to patients with cutaneous and musculoskeletal manifestations of chronic GVHD and were durable through 1 year after therapy. The median dose of prednisone among treated subjects fell from 40 mg/day to 10 mg/day, 1 year after rituximab therapy (P < .001). A chronic GVHD symptom score improved in the majority of treated patients. Antibody titers against Y chromosome-encoded minor HLA antigens fell and remained low, whereas titers against infectious antigens (EBV, tetanus) remained stable or rose during the treatment period. We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00136396.

[1]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[2]  N. Katoh,et al.  Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease , 2006, Leukemia.

[3]  R. Eisenberg,et al.  The therapeutic potential of anti-CD20 "what do B-cells do?". , 2005, Clinical immunology.

[4]  D. Weisdorf,et al.  Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. , 2005, Blood.

[5]  N. Treister,et al.  Scoring system for monitoring oral lichenoid lesions: a preliminary study. , 2005, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[6]  J. Ritz,et al.  Rituxan for steroid-refractory chronic GVHD , 2005 .

[7]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[8]  G. Ehninger,et al.  Petreatment with Rituximab Reduces the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with B Cell Lymphoma. , 2004 .

[9]  J. Ritz,et al.  Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis. , 2004 .

[10]  A. Cappione,et al.  Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[11]  J. G. van den Tweel,et al.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. , 2004, Blood.

[12]  I. Sanz,et al.  B cells as therapeutic targets for rheumatic diseases , 2004, Current opinion in rheumatology.

[13]  J. Ritz,et al.  Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.

[14]  B. Andersson,et al.  Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. , 2004, Experimental hematology.

[15]  J. Ritz,et al.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.

[16]  M. Becker,et al.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  A. Nagler,et al.  Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[18]  B. Gruhn,et al.  Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation , 2003, Bone Marrow Transplantation.

[19]  E. Lanino,et al.  Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. , 2003, Journal of hematotherapy & stem cell research.

[20]  S. Fenu,et al.  One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. , 2003, Haematologica.

[21]  E. Cook,et al.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[23]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[24]  M. Taniwaki,et al.  Effectiveness of rituximab for chemotherapy‐resistant multiple tumoral B‐LPD in a haemopoietic stem cell recipient , 2002, British journal of haematology.

[25]  Paul Martin,et al.  A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.

[26]  H. Deeg,et al.  Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. , 2001, Blood.

[27]  P. Mclaughlin,et al.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.

[28]  H. Lazarus,et al.  Chronic graft-versus-host disease: clinical manifestation and therapy , 2001, Bone Marrow Transplantation.

[29]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  G. Vogelsang How I treat chronic graft-versus-host disease. , 2001, Blood.

[31]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease , 2000 .

[32]  G. Yanik,et al.  Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease , 2000, Annals of Internal Medicine.

[33]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[34]  V. Leblond,et al.  Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  F. Berr,et al.  A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[37]  S. Seropian,et al.  Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation , 1999, Bone Marrow Transplantation.

[38]  C. Wheeler,et al.  Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation , 1998, Bone Marrow Transplantation.

[39]  H. Atkins,et al.  Quality of life following bone marrow transplantation: a comparison of patient reports with population norms , 1997, Bone Marrow Transplantation.

[40]  M. V. van Tol,et al.  The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. , 1996, Blood.